One of the things that makes developing effective treatments for Parkinson's disease so challenging is its complexity. While some forms are caused by genetics, others have environmental factors, and ...

Just as fluid biomarkers for amyloidosis and tau have revolutionized clinical studies of Alzheimer’s disease, α-synuclein markers are poised to do the same for Parkinson’s. With the advent of ...

Ever better experimental techniques allow us to perform experiments under tightly controlled conditions and can deliver gigantic amounts of data reflecting the complexity of biology. This has vastly ...